InvestorsObserver is giving Altimmune Inc (ALT) an Analyst Rating Rank of 80, meaning ALT is ranked higher by analysts than 80% of stocks. The average projection by analysts for ALT is $65 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
Investors Observer averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Altimmune Inc Stock Today?
Altimmune Inc (ALT) stock is down -3.11% while the S&P 500 has risen 0.39% as of 10:20 AM on Thursday, Sep 24. ALT has fallen -$0.39 from the previous closing price of $12.53 on volume of 168,578 shares. Over the past year the S&P 500 is up 8.86% while ALT has risen 503.98%. ALT lost -$2.21 per share the over the last 12 months.
Click Here to get the full report on Altimmune Inc (ALT) Stock.
